These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The AIDS Clinical Trials Unit experience: clinical research and antiviral treatment. Hendricksen C Nurs Clin North Am; 1988 Dec; 23(4):697-706. PubMed ID: 3057459 [TBL] [Abstract][Full Text] [Related]
24. Loss of zidovudine related mutations in the reverse transscriptase gene of HIV after switching therapy. Falkensammer B; El Attal R; Müllauer B; Sarcletti M; Parson W; Dierich MP; Stoiber H Eur J Med Res; 2002 Sep; 7(9):379-86. PubMed ID: 12435615 [TBL] [Abstract][Full Text] [Related]
25. Treatment of human immunodeficiency virus infections. Vogt MW; Hirsch MS Infect Dis Clin North Am; 1987 Jun; 1(2):323-39. PubMed ID: 3332793 [TBL] [Abstract][Full Text] [Related]
26. 3TC approval may revive AZT's appeal. Vazquez E Posit Aware; 1996; 7(1):8-9. PubMed ID: 11363136 [TBL] [Abstract][Full Text] [Related]
27. ACTG 175 and Delta. Torres G GMHC Treat Issues; 1995 Oct; 9(10):2-3. PubMed ID: 11362915 [TBL] [Abstract][Full Text] [Related]
29. Zidovudine. Powderly WG Mo Med; 1989 Nov; 86(11):741-3. PubMed ID: 2682195 [TBL] [Abstract][Full Text] [Related]
30. The role of didanosine in the management of HIV-1 infection. Gazzard BG; Moyle GJ Antivir Ther; 1997 Jul; 2(3):135-47. PubMed ID: 11322269 [TBL] [Abstract][Full Text] [Related]
31. Current perspectives on antiretroviral therapy. Fletcher CV Pharmacotherapy; 1993; 13(6):627-33. PubMed ID: 7508101 [TBL] [Abstract][Full Text] [Related]
32. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204 [TBL] [Abstract][Full Text] [Related]
33. New antiretrovirals and new combinations. Havlir DV; Lange JM AIDS; 1998; 12 Suppl A():S165-74. PubMed ID: 9632999 [TBL] [Abstract][Full Text] [Related]
34. All pregnant women advised to get HIV test, consider AZT therapy. AIDS Policy Law; 1995 Mar; 10(4):6-7. PubMed ID: 11362241 [TBL] [Abstract][Full Text] [Related]
35. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Olivero OA Environ Mol Mutagen; 2007; 48(3-4):215-23. PubMed ID: 16395695 [TBL] [Abstract][Full Text] [Related]
36. Fewer brain lesions with AZT. Posit Aware; 1996; 7(1):7. PubMed ID: 11363133 [TBL] [Abstract][Full Text] [Related]
37. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F; Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377 [TBL] [Abstract][Full Text] [Related]
38. Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy. Lewis W Antivir Ther; 2005; 10 Suppl 2():M13-27. PubMed ID: 16152703 [TBL] [Abstract][Full Text] [Related]
39. Management of patients with asymptomatic HIV infection. Bartlett JG Md Med J; 1990 Feb; 39(2):150-5. PubMed ID: 2406530 [TBL] [Abstract][Full Text] [Related]
40. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Phillips NC; Tsoukas C Blood; 1992 Mar; 79(5):1137-43. PubMed ID: 1371411 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]